Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)
1 Department of Dermatology, Henri-Mondor University Hospital, AP-HP , Créteil, France.
2 Paris Est Créteil University, EpiDermE, Créteil, France.
3 French Cutaneous Lymphomas Study Group (GFELC), France.
4 Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France.
5 Department of Dermatology, INSERM 1312, Bordeaux University Hospital, Bordeaux, France.
6 Department of Dermatology, Montpellier University Hospital, Montpellier, France.
7 Department of Dermatology, CHU Nantes, Nantes University, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France.
8 Department of Dermatology, Lille University Hospital, Lille, France.
9 Department of Dermatology, Saint-Pierre, Brugmann University Hospitals, Brussels, Belgium and Department of Hematology Bordet Institute, Brussels, Belgium.
10 Department of Dermatology, Rouen University Hospital, Rouen, France.
11 Department of Dermatology, Lausanne University Hospital, and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
12 Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France.
13 Department of Dermatology, Angers University Hospital, Angers, France.
14 Department of Dermatology, Rennes University Hospital, Rennes, France.
15 Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.
16 Department of Dermatology, Hôpital Nord, AP-HM, Marseille, France.
17 Department of Dermatology, Centre Hospitalier de Valence, Valence, France.
18 Department of Dermatology, Nice University Hospital, Nice, France.